General Information of the Protein
| Protein ID |
PT02461
|
||||
|---|---|---|---|---|---|
| Protein Name |
Neuronal acetylcholine receptor subunit alpha-4
|
||||
| Gene Name |
CHRNA4
|
||||
| Secondarily Gene Name |
NACRA4
|
||||
| Sequence |
MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI
Show/Hide
|
||||
| Organism |
Homo sapiens, Human
|
||||
| Protein Classification |
Ion channel
>
Ligand-gated ion channel
>
Nicotinic acetylcholine receptor
>
Nicotinic acetylcholine receptor alpha subunit
|
||||
| Function |
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Show/Hide
|
||||
| Uniprot ID |
Show/Hide
|
||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Subcellular Location |
Postsynaptic cell membrane
Cell membrane
Cell membrane
|
||||
Clinical Information about the Protein
Target 1 ( Neuronal acetylcholine receptor alpha-4 (CHRNA4) )
| Target Type | Successful Target | ||||
|---|---|---|---|---|---|
| Disease | 3 Target-related Diseases | 3 | |||
| 1 | Aneurysm [ICD-11: BD51.Z] | ||||
| 2 | Tobacco dependence [ICD-11: 6C4A.2] | ||||
| 3 | Alzheimer disease [ICD-11: 8A20] | ||||
| Approved Drug(s) | 1 Approved Drug | 1 | |||
| 1 | Trimethaphan | Approved | |||
| Clinical Trial Drug(s) | 1 Clinical Trial Drug | 1 | |||
| 1 | CYTISINE | Phase 3 | |||
| Discontinued Drug(s) | 1 Discontinued Drug | 1 | |||
| 1 | ABT-418 | Discontinued in Phase 2 | |||